Coya Therapeutics (COYA) financial statements
Coya Therapeutics reported revenue of $8M in fiscal 2025, up 15.1% a year over 2 years.
Net income was -$21M.
The diluted share count rose 546% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Coya Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | $0 | $6M | $4M | $8M |
| Research and development | $3M | $4M | $6M | $12M | $17M |
| Selling, general and admin | $2M | $5M | $8M | $9M | $11M |
| Operating income | -$5M | -$10M | -$8M | -$17M | -$23M |
| Pre-tax income | — | -$12M | -$7M | -$16M | -$21M |
| Income tax | — | $0 | $723,852 | -$720,287 | $3,089 |
| Net income | -$5M | -$12M | -$8M | -$15M | -$21M |
| EPS (diluted) | -$1.89 | -$4.73 | -$0.79 | -$0.98 | -$1.27 |
| Diluted shares | 3M | 3M | 10M | 15M | 17M |
| Operating margin | — | — | -131.7% | -485.4% | -283.9% |
| Net margin | — | — | -133.1% | -418.7% | -267.1% |
Balance sheet
Fiscal years, from Coya Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and short-term investments | $4M | $6M | $33M | $38M | $47M |
| Total current assets | $5M | $7M | $41M | $44M | $50M |
| Property, plant and equipment | $120,671 | $93,310 | $65,949 | $38,588 | $11,227 |
| Total assets | $5M | $8M | $41M | $44M | $50M |
| Total current liabilities | $1M | $4M | $5M | $4M | $6M |
| Total liabilities | $1M | $17M | $6M | $5M | $7M |
| Shareholders' equity | $4M | -$8M | $36M | $40M | $43M |
| Net debt | -$4M | -$6M | -$33M | -$38M | -$47M |
Cash flow
Fiscal years, from Coya Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating cash flow | -$4M | -$7M | -$11M | -$10M | -$11M |
| Stock-based compensation | $233,222 | $207,346 | $872,248 | $3M | $4M |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for COYA.
Open COYA in InvestinglyQuestions
What was Coya Therapeutics's revenue in 2025?
$8M in fiscal 2025, from its 10-K filing.
From Coya Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.